Today on Pharmaceutical Processing
How end-to-end visibility and machine learning can safeguard the vaccine supply chain
Fauci: J&J vaccination could resume shortly
Sponsored Content See More >
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Regulatory See More >
FDA releases scathing inspection report regarding Emergent BioSolutions plant
An FDA report cites multiple failures in an Emergent BioSolutions plant tapped to produce vaccines for Johnson & Johnson and AstraZeneca. The vaccine plant had been forced to discard up to 15 million doses of Johnson & Johnson’s COVID-19 vaccine in a single manufacturing batch. Emergent BioSolutions recently paused production of the vaccine during the FDA inspection and…
Facility See More >
Johnson & Johnson COVID-19 vaccine shipments plunge
Johnson & Johnson will cut COVID-19 vaccine shipments by 86% in the coming week, according to CDC projections. The week of April 5, the company shipped nearly 5 million doses. Next week, that figure could fall to approximately 700,000. The company anticipates that it can eventually deliver up to 8 million doses weekly, assuming FDA authorizes…
Supply Chain See More >
How end-to-end visibility and machine learning can safeguard the vaccine supply chain
For any vaccine, some degree of waste is expected. The problem is inspiring supply-chain companies to explore new technologies that can address a longstanding struggle. “Before COVID-19, we often saw waste of about 8–10%,” said Ranjeet Banerjee, CEO of Cold Chain Technologies, which provides insulated packaging for drugs and biologics. A 2019 World Health Organization report citing…
Recalls See More >
GSK, Pfizer and J&J among the most-fined drug companies, according to study
GlaxoSmithKline (LON:GSK) paid nearly $10 billion in inflation-adjusted financial penalties between January 2003 and December 2016, the highest tally for any drug company, according to research published in JAMA. That sum was more than any other in a sampling of 26 companies paying fines inside the U.S. Pfizer (NYSE: PFE) was next in line with…
Nostrum Laboratories recalls Type 2 diabetes drug over contamination problems
Flu vaccination worries rise in South Korea following deaths
Torrent Pharmaceuticals Issues Voluntary Nationwide Recall of Losartan Potassium Tablets
